<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_AFOS292 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEfx1 jpg ?>
<?FILEsi1 svg ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Osteoporos Sarcopenia</journal-id>
    <journal-id journal-id-type="iso-abbrev">Osteoporos Sarcopenia</journal-id>
    <journal-title-group>
      <journal-title>Osteoporosis and Sarcopenia</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">2405-5255</issn>
    <issn pub-type="epub">2405-5263</issn>
    <publisher>
      <publisher-name>Korean Society of Osteoporosis</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10627863</article-id>
    <article-id pub-id-type="pii">S2405-5255(23)00048-1</article-id>
    <article-id pub-id-type="doi">10.1016/j.afos.2023.08.002</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>BONEcheck: A digital tool for personalized bone health assessment</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Nguyen</surname>
          <given-names>Dinh Tan</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Ho-Le</surname>
          <given-names>Thao P.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Pham</surname>
          <given-names>Liem</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Ho-Van</surname>
          <given-names>Vinh P.</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Hoang</surname>
          <given-names>Tien Dat</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Tran</surname>
          <given-names>Thach S.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff4" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author" id="au7">
        <name>
          <surname>Frost</surname>
          <given-names>Steve</given-names>
        </name>
        <xref rid="aff5" ref-type="aff">e</xref>
      </contrib>
      <contrib contrib-type="author" id="au8">
        <name>
          <surname>Nguyen</surname>
          <given-names>Tuan V.</given-names>
        </name>
        <email>tuanvan.nguyen@uts.edu.au</email>
        <xref rid="aff1" ref-type="aff">a</xref>
        <xref rid="aff6" ref-type="aff">f</xref>
        <xref rid="aff7" ref-type="aff">g</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <aff id="aff1"><label>a</label>School of Biomedical Engineering, University of Technology, Sydney, Australia</aff>
      <aff id="aff2"><label>b</label>Saigon Precision Medicine Research Center, Ho Chi Minh, Viet Nam</aff>
      <aff id="aff3"><label>c</label>Faculty of Engineering and Information Technology, Hatinh University, Hatinh, Viet Nam</aff>
      <aff id="aff4"><label>d</label>Garvan Institute of Medical Research, Sydney, Australia</aff>
      <aff id="aff5"><label>e</label>University of Wollongong, Wollongong, Australia</aff>
      <aff id="aff6"><label>f</label>Tam Anh Research Institute, Ho Chi Minh, Viet Nam</aff>
      <aff id="aff7"><label>g</label>School of Population Health, UNSW Sydney, Australia</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author. School of Biomedical Engineering University of Technology, Sydney (UTS) Broadway, Ultimo NSW 2007, Australia. <email>tuanvan.nguyen@uts.edu.au</email></corresp>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>19</day>
      <month>9</month>
      <year>2023</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="ppub">
      <month>9</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>19</day>
      <month>9</month>
      <year>2023</year>
    </pub-date>
    <volume>9</volume>
    <issue>3</issue>
    <fpage>79</fpage>
    <lpage>87</lpage>
    <history>
      <date date-type="received">
        <day>2</day>
        <month>6</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>7</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>14</day>
        <month>8</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Korean Society of Osteoporosis</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <sec>
        <title>Objectives</title>
        <p>Osteoporotic fracture is a significant public health burden associated with increased mortality risk and substantial healthcare costs. Accurate and early identification of high-risk individuals and mitigation of their risks is a core part of the treatment and prevention of fractures. Here we introduce a digital tool called 'BONEcheck' for personalized assessment of bone health.</p>
      </sec>
      <sec>
        <title>Methods</title>
        <p>The development of BONEcheck primarily utilized data from the prospective population-based Dubbo Osteoporosis Epidemiology Study and the Danish Nationwide Registry. BONEcheck has 3 modules: input data, risk estimates, and risk context. Input variables include age, gender, prior fracture, fall incidence, bone mineral density (BMD), comorbidities, and genetic variants associated with BMD.</p>
      </sec>
      <sec>
        <title>Results</title>
        <p>Based on the input variables, BONEcheck estimates the probability of any fragility fracture and hip fracture within 5 years, subsequent fracture risk, skeletal age, and time to reach osteoporosis. The probability of fracture is shown in both numeric and human icon array formats. The risk is also contextualized within the framework of treatment and management options on Australian guidelines, with consideration given to the potential fracture risk reduction and survival benefits. Skeletal age was estimated as the sum of chronological age and years of life lost due to a fracture or exposure to risk factors that elevate mortality risk.</p>
      </sec>
      <sec>
        <title>Conclusions</title>
        <p>BONEcheck is an innovative tool that empowers doctors and patients to engage in well-informed discussions and make decisions based on the patient's risk profile. Public access to BONEcheck is available via <ext-link ext-link-type="uri" xlink:href="https://bonecheck.org" id="intref0010">https://bonecheck.org</ext-link> and in Apple Store (iOS) and Google Play (Android).</p>
      </sec>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Keywords</title>
      <kwd>BONEcheck</kwd>
      <kwd>Risk prediction</kwd>
      <kwd>Risk assessment tools</kwd>
      <kwd>Osteoporosis prediction</kwd>
      <kwd>Research translation</kwd>
      <kwd>BONEcheck guidelines</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p id="p0010">Osteoporosis is a skeletal condition characterized by reduced bone mass and deteriorated bone microstructure, leading to an increased risk of fracture. Globally, osteoporosis affects over 200 million people aged 50 years and older [<xref rid="bib1" ref-type="bibr">1</xref>], with women being more susceptible than men. In addition, there are 178 million fractures, including 14.2 million hip fractures which is the most severe manifestation of osteoporosis [<xref rid="bib2" ref-type="bibr">2</xref>]. An existing fracture is associated with an increased risk of further fractures [<xref rid="bib3" ref-type="bibr">3</xref>] and an increased risk of premature mortality [<xref rid="bib4" ref-type="bibr">4</xref>]. With the ongoing aging population worldwide, it is expected that the burden and consequences of fractures will be more pronounced in the future.</p>
    <p id="p0015">A significant proportion of osteoporotic fractures and fracture-associated deaths is preventable by either taking a treatment or preventive measures. However, at present, there is a crisis of osteoporosis management in which most patients with a fracture are not treated. Moreover, even among those on treatment, adherence has been poor, with many patients opting out of the treatment program [<xref rid="bib5" ref-type="bibr">5</xref>]. Therefore, a research priority in osteoporosis is to identify high-risk individuals for treatment and prevention. Over the past 2 decades, fracture risk assessment tools such as the Garvan Fracture Risk Calculator [<xref rid="bib6" ref-type="bibr">6</xref>] and FRAX [<xref rid="bib7" ref-type="bibr">7</xref>] have been developed and implemented in clinical practice. These tools map clinical risk factors to the probability of fractures over 5-year or 10-year for an individual. The implementation of fracture risk calculators represents a significant advance in the field.</p>
    <p id="p0020">Despite the advance, existing fracture risk calculators have a number of limitations in terms of form and communication. First, they use probability as a metric of risk, which is not readily understood by laypeople and doctors alike, especially when the probability is not presented in the context of the treatment [<xref rid="bib8" ref-type="bibr">8</xref>]. Second, the presentation of risk is in a purely numerical format which is known to be less effective than a frequency format [<xref rid="bib9" ref-type="bibr">9</xref>]. Third, existing risk calculators do not assess the risk of refracture and mortality, which are highly relevant to an individual. The lack of post-fracture mortality assessment might have led to the underappreciation of osteoporosis as a serious disease. These major limitations call for a more effective and innovative risk assessment tool.</p>
    <p id="p0025">In this paper, we describe the development and implementation of a digital fracture risk assessment tool that addresses the above limitations. The new tool is called 'BONEcheck' and is available free worldwide. It is anticipated that the tool will help facilitate doctor-patient communication about fracture risk, its survival consequences, and interventional options.</p>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Methods</title>
    <p id="p0030">BONEcheck includes 3 modules: input data, risk estimates, and risk interpretation or contextualization. The input data are determined from previous studies that have identified relevant and independent risk factors for fracture [<xref rid="bib10" ref-type="bibr">[10]</xref>, <xref rid="bib11" ref-type="bibr">[11]</xref>, <xref rid="bib12" ref-type="bibr">[12]</xref>]. The output information is designed from patients' perspectives and presented in a format that is meaningful to patients. This output is contextualized in relation to treatment and preventive measures. The language used in the interpretation of risk estimates and risk management is written for individuals whose reading level is at or above 8.</p>
    <p id="p0035">To begin, we conducted a comprehensive review of previous studies and prediction models related to bone health. We carefully examined their methodologies, variables, and parameter settings. Recognizing the variations and potential mismatches across different studies, we sought to reproduce their results while standardizing the variables and addressing discrepancies.</p>
    <p id="p0040">One particular challenge we encountered was the variation in variables scales used in different studies. To overcome this, we standardized the variables across all datasets and models to maintain consistency and comparability. Additionally, we ensured that other variables, such as prior fracture, fall incidence, bone mineral density (BMD), comorbidities, and genetic variants associated with BMD, were appropriately standardized and adjusted to match the requirements of the BONEcheck tool. In order to maintain similar performance across models, we carefully adjusted certain parameters to ensure that BONEcheck delivered accurate and reliable risk estimates. This involved fine-tuning the algorithms and calibration to optimize the predictive power of the tool.</p>
    <p id="p0045">In the development of BONEcheck, we utilized several datasets to incorporate relevant information and build the risk prediction algorithm. The datasets were as follows.<list list-type="simple" id="ulist0010"><list-item id="u0010"><label>•</label><p id="p0050">The Dubbo Osteoporosis Epidemiology Study (DOES) [<xref rid="bib10" ref-type="bibr">10</xref>]: The study was designed as a population-based prospective investigation that has followed more than 3000 men and women aged 50 years and older for up to 30 years. This dataset was used to develop the Garvan Fracture Risk Calculator for predicting the risks of fracture and refracture, which is an algorithm within BONEcheck.</p></list-item><list-item id="u0015"><label>•</label><p id="p0055">Danish Nationwide Registry [<xref rid="bib11" ref-type="bibr">11</xref>] is a comprehensive and population-based registry that contains health-related data on all individuals in Denmark. This dataset was used to estimate the skeletal age for each fracture site.</p></list-item><list-item id="u0020"><label>•</label><p id="p0060">DOES [<xref rid="bib14" ref-type="bibr">13</xref>], Study of Osteoporotic Fractures (SOF) [<xref rid="bib15" ref-type="bibr">14</xref>], and Osteoporotic Fractures in Men study (MrOS) [<xref rid="bib12" ref-type="bibr">12</xref>]: These datasets were used to estimate the annual rate of change in BMD, and from which, the time to reach osteoporosis (ie, T-scores <inline-formula><mml:math id="M1" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">≤</mml:mo></mml:mrow></mml:math></inline-formula> −2.5) in BONEcheck.</p></list-item></list></p>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Input data</title>
      <p id="p0065">BONEcheck uses a range of variables that capture the uniqueness of the risk profile for an individual. These variables include anthropometric data (eg, age, gender, height, and weight), lifestyle factors (eg, smoking habit and alcohol consumption), and bone-related data such as femoral neck BMD and a personal history of fracture. We chose to use femoral neck BMD rather than lumbar spine BMD because the former has been shown to be less prone to artefactual errors due to degenerative changes. BMD can be entered either in absolute values (gram per cm<sup>2</sup>) or T-score, which is the number of standards deviation from the peak BMD taken as aged between 20 and 30 years. Individuals with a T-score equal to or less than −2.5 is diagnosed to have 'osteoporosis'. The computation, however, uses actual continuous BMD measurement, not T-scores. The personal history of fracture is entered as the number of prior fractures, not a binary value of 'yes' or 'no'.</p>
      <p id="p0070">In addition, BONEcheck also requires input data pertaining to fall history, existing comorbidities, and a genetic profile. The number of falls over the previous 12 months is used for estimating the risk of fracture. Existing comorbidities include a list of 11 chronic conditions (<xref rid="tbl1" ref-type="table">Table 1</xref>), with each condition being entered as 'yes' or 'no'. Based on the self-reported comorbidities, BONEcheck calculates the Charlson Comorbidity Index (CCI) [<xref rid="bib16" ref-type="bibr">15</xref>], which is used as a risk factor for the estimation of post-fracture mortality and skeletal age.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Input variables and output information in BONEcheck.</p></caption><alt-text id="alttext0025">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Group</th><th>Input and output factors</th><th>Valid values</th><th>Definition</th></tr></thead><tbody><tr><td rowspan="5" align="left">Baseline data</td><td align="left">Age, yr</td><td align="left">50–96</td><td align="left">Chronological age</td></tr><tr><td align="left">Gender</td><td align="left">Man/Woman</td><td align="left">Character variable</td></tr><tr><td align="left">Height, cm</td><td align="left">100–274</td><td align="left">Current height in cm</td></tr><tr><td align="left">Weight, kg</td><td align="left">30–150</td><td align="left">Current weight in kg</td></tr><tr><td align="left">Smoking</td><td align="left">Yes/No</td><td align="left">Current smoking status</td></tr><tr><td rowspan="5" align="left">Bone properties (5 variables)</td><td align="left">Previous fragility fractures</td><td align="left">0–3</td><td align="left">Number of fractures from the age of 50 years</td></tr><tr><td align="left">Falls history</td><td align="left">0–3</td><td align="left">Number of falls over the last 12 months</td></tr><tr><td align="left">BMD, g/cm<sup>2</sup></td><td align="left">0.6–1.4</td><td align="left">Femoral neck bone mineral density</td></tr><tr><td align="left">T-score</td><td align="left">−5 to +4</td><td align="left">Number of standard deviations from the peak bone density</td></tr><tr><td align="left">Densitometer</td><td align="left">GE/Hologic</td><td align="left">Manufacturer of densitometer</td></tr><tr><td rowspan="14" align="left">Comorbidity (14 variables)</td><td align="left">Cardiovascular disease</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Neuromuscular</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Congestive heart failure</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Dementia</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Chronic obstructive pulmonary disease (COPD)</td><td align="left">Yes/No</td><td align="left">Binary variable, may include asthma</td></tr><tr><td align="left">Diabetes with chronic complications</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Rheumatologic disease</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Metastatic solid tumor</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Mild liver disease</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Moderate or severe liver disease</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Renal disease</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Hemiplegia or paraplegia</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Any malignancy, including leukemia and lymphoma</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">AIDS/HIV</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td rowspan="15" align="left">Fracture (15 variables)</td><td align="left">Hip</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Pelvis</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Femur</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Vertebrae</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Humerus</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Rib</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Clavicle</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Tibia</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Elbow</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Forearm</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Knee</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Ankle</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Foot</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Hand</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Wrist</td><td align="left">Yes/No</td><td align="left">Binary variable</td></tr><tr><td align="left">Osteogenomic profile</td><td align="left">Genetic profile</td><td align="left">Selected option</td><td align="left">33 genotypes related to fracture risk</td></tr><tr><td rowspan="8" align="left">Results/output</td><td align="left">5-year any fracture risk</td><td align="left">1–100</td><td align="left">Probability of fracture</td></tr><tr><td align="left">5-year fracture risk with intervention</td><td align="left">1–100</td><td align="left">Probability of fracture</td></tr><tr><td align="left">5-year hip fracture risk</td><td align="left">1–100</td><td align="left">Probability of fracture</td></tr><tr><td align="left">5-year hip fracture risk with intervention</td><td align="left">1–100</td><td align="left">Probability of fracture</td></tr><tr><td align="left">Subsequent fracture risk</td><td align="left">1–100</td><td align="left">Probability of fracture</td></tr><tr><td align="left">Genetic risk score</td><td align="left">1–100</td><td align="left">Accumulated number of 'risk alleles'</td></tr><tr><td align="left">Skeletal age</td><td align="left">0–10</td><td align="left">Years</td></tr><tr><td align="left">Time to reach osteoporosis</td><td align="left">0–120</td><td align="left">Duration in months</td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold> An overview of the parameter groupings is listed such as demographic factors, fracture history, bone mineral density, comorbidities, and genetic variants associated with BMD. The second column lists the names of each parameter, providing specific details on what each parameter represents. The third column displays the refined validity of the parameter values, indicating the appropriate range or acceptable values for each parameter. The last column provides definitions for each parameter, further clarifying their meaning and interpretation.</p></fn></table-wrap-foot></table-wrap></p>
      <p id="p0075">The genetic profile included 34 genetic variants that have been shown to be associated with BMD in a genome-wide association study [<xref rid="bib17" ref-type="bibr">16</xref>]. Each genetic variant is inputted as the number of minor alleles. Based on the data, an 'Osteogenomic Profile' for each individual is generated as the weighted sum of the number of minor alleles across variants, with the weights being the published regression coefficient associated with each minor allele [<xref rid="bib18" ref-type="bibr">17</xref>]. This Osteogenomic Profile, which has been shown to be associated with the fracture risk [<xref rid="bib18" ref-type="bibr">17</xref>] and bone loss [<xref rid="bib19" ref-type="bibr">18</xref>] in the elderly, is used as an input variable for estimating the risk of fractures.</p>
      <p id="p0080">The flow of input variables and output information is shown in <xref rid="fig1" ref-type="fig">Fig. 1</xref>. The web application's input was designed using the web application concept, which does not store or save any input data to keep privacy and confidentiality for users. Additionally, BONEcheck allows users to create accounts to save their results for future comparison and provides the option for users to delete their accounts if desired.<fig id="fig1"><label>Fig. 1</label><caption><p>The flow of input variables and output in the BONEcheck system. The left column shows the input variables and the right column displays the output variables. For instance, the input variables of age, sex, weight, previous fracture, previous falls, and BMD were used to estimate the risk of fracture. The genetic risk score was also used as an option variable to estimate fracture risk.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Output information</title>
      <p id="p0085">Based on the input variables, a series of output information is produced. These outputs are related to (a) the risk of fracture; (b) skeletal age; and (c) bone loss assessment. <italic>The risk of fracture</italic> is presented as the absolute probability of any fracture and hip fracture over the next 5 years. We chose to focus on 5-year window because that is the ideal time for an individual to manage their risk. In addition to numerical probability, we also provide a frequency of human icons to capture the risk visually. For instance, a 10% risk is presented as 10 red icons in 100 human icons. Because an existing fracture is a signal of further fractures, we also provide the risk of refracture if a fracture has been sustained. The risk of refracture is presented in a numerical probability over the next 2 years using the published model [<xref rid="bib11" ref-type="bibr">11</xref>]. In addition, any fracture risk is classified as a risk gradient as follows: "high risk" if 5-year fracture probability exceeds 8%; "medium risk" if the probability ranges between 5 and 8%; and "low risk" if the probability is below 5%. When it comes to hip fracture, “high risk” signifies a risk greater than 2%, “medium risk” represents a risk between 1% and 2%, and “low risk” indicates a risk level lower than 1%.</p>
      <p id="p0090"><italic>Skeletal age</italic> is a new metric of fracture risk assessment. Conceptually, skeletal age is the age of an individual's skeleton because of a fracture or being exposed to risk factors that elevate the risk of fracture [<xref rid="bib20" ref-type="bibr">19</xref>]. Operationally, skeletal age is defined as the sum of an individual's actual age and the years of life lost associated with a fracture or exposure to risk factors that put an individual at a greater risk of fracture. Years of life lost is based on the comparison between the age of death to the standard life expectancy that is available in a national lifetable [<xref rid="bib21" ref-type="bibr">20</xref>]. BONEcheck integrates the risk of fracture and the US lifetable to estimate the years of life lost associated with a fracture and then determined the skeletal age.</p>
      <p id="p0095"><italic>Bone loss assessment</italic>. Using published findings [<xref rid="bib22" ref-type="bibr">21</xref>,<xref rid="bib23" ref-type="bibr">22</xref>], BONEcheck estimates the rate of change in femoral neck BMD for those aged 50 years and older stratified by baseline BMD. From the estimated rate of change, the algorithm uses linear regression to determine the time to reach 'osteoporosis' (ie, T-scores <inline-formula><mml:math id="M2" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">≤</mml:mo></mml:mrow></mml:math></inline-formula> −2.5). There is additional advice that users need to consult with their doctors to determine the time to repeat BMD measurement.</p>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Interpretation/contextualization</title>
      <p id="p0100">In addition to risk estimates, BONEcheck provides interpretations of the probability of fracture tailored to an individual's risk profile. The risk is presented in two scenarios: not treatment and on treatment. The interpretation is based on the 'frequentist' school of probability, not subjective probability. Thus, a fracture probability of 10% is interpreted as 10 fractures in 100 men/women like the individual. The reduction of risk was derived from published results of randomized controlled trials [<xref rid="bib24" ref-type="bibr">23</xref>]. The probability of fracture is then referred to the current Australian Pharmaceutical Benefits Scheme (PBS), which states that individuals with a 5-year fracture probability of 8–13% or higher are eligible for reimbursement.</p>
      <p id="p0105">For skeletal age, it explicitly acknowledges that a fracture is correlated with a reduction in life expectancy, with a corresponding interpretation provided. If an individual's skeletal age surpasses their chronological age, it indicates that the individual is at a greater risk of fracture and mortality when compared to other people of the same age and gender. For those without a fracture, the number of years of life lost is determined as the product of the remaining lifetime risk of fracture and the number of years of life lost associated with a hip fracture, stratified by gender and age. Users are advised that by implementing preventative measures or following a bone specialist's recommended effective treatment, they can decrease their skeletal age.</p>
      <p id="p0110">There is a 'Prevention' tab where users can learn about preventive measures to reduce their risk of fracture and improve their BMD measurement. The advice given in the Prevention tab is based on current guidelines for the treatment and prevention of osteoporosis [<xref rid="bib25" ref-type="bibr">24</xref>].</p>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results</title>
    <p id="p0115">The web-based graphical interface of BONEcheck is shown in <xref rid="fig2" ref-type="fig">Fig. 2</xref>. The tool collects each individual's input data; processes the data; loads the algorithms or training models; calculates the metrics, and displays the results of calculation and interpretation. The risk of fracture is 'individualized' in the sense that each individual has a unique probability of fracture which is calculated from the individual's unique risk profile. This unique profile is defined in terms of the 'Osteogenomic profile' and other clinical parameters. For illustration, <xref rid="tbl2" ref-type="table">Table 2</xref> presents the output of BONEcheck for 4 individuals.<list list-type="simple" id="ulist0015"><list-item id="u0025"><label>•</label><p id="p0120"><italic>Individual A</italic>: woman, 65 years old, has sustained a hip fracture, 1 fall over the past 12 months, T-score is −2.0, has type 2 diabetes, no genetic profile data.</p></list-item><list-item id="u0030"><label>•</label><p id="p0125"><italic>Individual B</italic>: woman, 65 years old, has no fracture, no fall, T-score is −2.5, has congestive heart failure, genetic profile data.</p></list-item><list-item id="u0035"><label>•</label><p id="p0130"><italic>Individual C</italic>: man, 65 years old, has 1 vertebral fracture, 1 fall, T-score is −2.0, has type 2 diabetes mellitus, no genetic profile data.</p></list-item><list-item id="u0040"><label>•</label><p id="p0135"><italic>Individual D</italic>: man, 65 years old, has no vertebral fracture, no fall, T-score is −2.5, has COPD, genetic profile data.</p></list-item></list><fig id="fig2"><label>Fig. 2</label><caption><p>Input screen of BONEcheck.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Illustration of BONEcheck with 4 hypothetical cases.</p></caption><alt-text id="alttext0030">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Profile</th><th>Individual A</th><th>Individual B</th><th>Individual C</th><th>Individual D</th></tr></thead><tbody><tr><td align="left">Gender</td><td align="left">Woman</td><td align="left">Woman</td><td align="left">Man</td><td align="left">Man</td></tr><tr><td align="left">Age, yr</td><td align="left">65</td><td align="left">65</td><td align="left">65</td><td align="left">65</td></tr><tr><td align="left">Weight, kg</td><td align="left">45</td><td align="left">45</td><td align="left">45</td><td align="left">45</td></tr><tr><td align="left">Prior fracture</td><td align="left">Hip</td><td align="left">No</td><td align="left">Vertebral</td><td align="left">No</td></tr><tr><td align="left">Number of falls over the past 12 months</td><td align="left">1</td><td align="left">No</td><td align="left">1</td><td align="left">No</td></tr><tr><td align="left">T-score</td><td align="left">−2.0</td><td align="left">−2.5</td><td align="left">−2.0</td><td align="left">−2.5</td></tr><tr><td align="left">Comorbidity<xref rid="tbl2fn1" ref-type="table-fn">1</xref>, <xref rid="tbl2fn2" ref-type="table-fn">2</xref>, <xref rid="tbl2fn3" ref-type="table-fn">3</xref></td><td align="left">DM</td><td align="left">CHF</td><td align="left">DM</td><td align="left">COPD</td></tr><tr><td align="left">Genetic profile available</td><td align="left">No</td><td align="left">Yes</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td colspan="5" align="left"><bold>Output</bold></td></tr><tr><td align="left">5-year risk of any fracture with BMD</td><td align="left">15%</td><td align="left">9%</td><td align="left">11%</td><td align="left">5%</td></tr><tr><td align="left">5-year risk of any fracture without BMD</td><td align="left">16%</td><td align="left">7%</td><td align="left">6%</td><td align="left">2%</td></tr><tr><td align="left">5-year risk of hip fracture with BMD</td><td align="left">5%</td><td align="left">2%</td><td align="left">2%</td><td align="left">1%</td></tr><tr><td align="left">5-year risk of hip fracture without BMD</td><td align="left">2%</td><td align="left">1%</td><td align="left">2%</td><td align="left">1%</td></tr><tr><td align="left">Genetic risk score</td><td/><td align="left">3.85%</td><td/><td align="left">3.57%</td></tr><tr><td align="left">Risk of refracture</td><td align="left">22%</td><td align="left">12.6%</td><td align="left">13%</td><td align="left">11%</td></tr><tr><td align="left">Skeletal age</td><td align="left">70.3</td><td align="left">67.9</td><td align="left">70.1</td><td align="left">66.9</td></tr><tr><td align="left">Time to reach osteoporosis</td><td align="left">22 months</td><td align="left">0 months</td><td align="left">20 months</td><td align="left">0 months</td></tr></tbody></table><table-wrap-foot><fn id="tbl2fn1"><label>1</label><p id="ntpara0015">DM, diabetes mellitus.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn2"><label>2</label><p id="ntpara0020">CHF, congestive heart failure.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fn3"><label>3</label><p id="ntpara0025">COPD, chronic obstructive pulmonary disease.</p></fn></table-wrap-foot></table-wrap></p>
    <p id="p0140">As can be seen from <xref rid="tbl2" ref-type="table">Table 2</xref>, for the same age and gender, the risk of fracture (any fracture and hip fracture) is inversely associated with femoral neck BMD T-scores, and for the same age and T-score, women, as expected, have a higher risk of fracture than men. For those with an existing fracture, the risk of refracture is relatively high for a shorter duration.</p>
    <p id="p0145">The risk of fracture is also presented in a human icon format (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). In this presentation of 100 icons, the ones with a fracture are shown in red color, and the benefit of treatment (in terms of fracture risk reduction) is shown in green color. This is accompanied by an interpretation as follows (for individual A):<disp-quote id="disp0010"><p>"Based on the information you provided, it is estimated that your 5-year risk of any fracture is: 15%. This means that among 100 women like you (eg, the same age and the same risk profile), 15 (red color) will suffer a fracture in the next 5 years, and 85 (grey color) will not. However, with effective treatment, your risk of any fracture within the next 5 years is reduced to 9, resulting in a benefit for 6 (green color) out of every 100 women who receive the treatment."</p></disp-quote><fig id="fig3"><label>Fig. 3</label><caption><p>An example of output screen of BONEcheck.</p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p>
    <p id="p0150">A similar output and interpretation are also provided for hip fracture risk.</p>
    <p id="p0155">The skeletal age analysis shows that a hip fracture confers a greater impact on the years of life lost and results in a higher skeletal age than a vertebral fracture. A 65-year-old woman who has sustained a hip fracture is predicted to have a skeletal age of 70.3 years (individual A). Moreover, the skeletal age of a 65-year-old man who has sustained a vertebral fracture is estimated to be 70.1 years (individual C). The skeletal age output is also accompanied by a graphical format (<xref rid="fig3" ref-type="fig">Fig. 3</xref>) with an interpretation as follows (individual A):<disp-quote id="disp0015"><p>"Based on the information you have provided, given your current age of 65 years old and your estimated skeletal age of 70.3 (the gap is 5.3), it means that you have an increased risk of fracture. More specifically, you are now in the same risk category as a 70.3-years old with 'favorable risk factors' or at least the ones that are potentially modifiable. Please see the 'Prevention' tab of BONEcheck for preventive measures."</p></disp-quote></p>
    <p id="p0160">The time to reach osteoporosis (ie, T-scores <inline-formula><mml:math id="M3" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">≤</mml:mo></mml:mrow></mml:math></inline-formula> −2.5) is estimated based on current age and BMD measurement. Thus, for an individual with a current T-score = −2.0, it is estimated that the time to reach osteoporosis (T &lt; −2.5) is 22 months (for women) and 20 months (for men). If the current T-score <inline-formula><mml:math id="M4" altimg="si1.svg"><mml:mrow><mml:mo linebreak="goodbreak" linebreakstyle="after">≤</mml:mo></mml:mrow></mml:math></inline-formula> −2.5, then the output will read "<italic>You are having osteoporosis. You should discuss with your doctor for a treatment option and a repeat bone density measurement.</italic>"</p>
    <p id="p0165">All output information can be saved into a file or an internet link so users can use it to discuss with their doctor. The saved information can also be used for longitudinal comparison for a user.</p>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Discussion</title>
    <p id="p0170">Fracture due to osteoporosis remains a significant burden worldwide because it is associated with an increased risk of premature mortality and substantial healthcare costs. An essential effort of fracture prevention focuses on the identification of high-risk individuals for intervention, and a number of risk assessment tools have been developed and implemented for this purpose. However, none of the tools incorporates pre-mature mortality and risk contextualization. Moreover, the majority of osteoporosis patients are not treated or do not adhere to treatment guidelines due in part to poor risk communication. In order to address those shortcomings, we have developed the BONEcheck system for public use with the hope of contributing to the reduction of the global burden of osteoporosis.</p>
    <p id="p0175">The difference in output between BONEcheck and existing algorithms is shown in <xref rid="tbl3" ref-type="table">Table 3</xref>. Existing fracture risk assessment tools such as the Garvan Fracture Risk Calculator [<xref rid="bib6" ref-type="bibr">6</xref>], FRAX [<xref rid="bib7" ref-type="bibr">7</xref>], and Qfracture [<xref rid="bib26" ref-type="bibr">25</xref>] provide 5-year [<xref rid="bib6" ref-type="bibr">6</xref>] or 10-year [<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>] risk of any fracture or osteoporotic fracture and hip fracture. The present BONEcheck utilizes the Garvan Fracture Risk Calculator algorithm to estimate 5-year risk of fracture. The performance of the Garvan Fracture Risk Calculator has been extensively validated through external studies and reviewed elsewhere [<xref rid="bib27" ref-type="bibr">26</xref>]. The results of these validation studies [<xref rid="bib28" ref-type="bibr">[27]</xref>, <xref rid="bib29" ref-type="bibr">[28]</xref>, <xref rid="bib30" ref-type="bibr">[29]</xref>] have indicated that the Garvan model performed as well as or usually better than the FRAX model in terms of fracture discrimination and accuracy.<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Comparison between existing fracture risk assessment tools.</p></caption><alt-text id="alttext0035">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Tool functions</th><th>FRAX</th><th>Garvan</th><th>QFracture</th><th>BONEcheck</th></tr></thead><tbody><tr><td align="left">5-year fracture risk</td><td align="left">–</td><td align="left">–</td><td align="left">+</td><td align="left">+</td></tr><tr><td align="left">10-year fracture risk</td><td align="left">+</td><td align="left">+</td><td align="left">+</td><td align="left">–</td></tr><tr><td align="left">Subsequent fracture risk</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">+</td></tr><tr><td align="left">Polygenic risk score</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">+</td></tr><tr><td align="left">Skeletal age</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">+</td></tr><tr><td align="left">Time to reach osteoporosis</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">+</td></tr><tr><td align="left">Risk contextulization</td><td align="left">–</td><td align="left">–</td><td align="left">–</td><td align="left">+</td></tr><tr><td align="left">Interpretation</td><td align="left">–</td><td align="left">–</td><td align="left">+</td><td align="left">+</td></tr></tbody></table></table-wrap></p>
    <p id="p0180">The predicted risk of fracture is different between algorithms due largely to underlying statistical models and input variables. Although FRAX's predicted risk is adjusted to account for the competing risk of mortality, the method of adjustment has not been disclosed. On the other hand, the Garvan model was created using data from the Dubbo Osteoporosis Epidemiology Study, where each individual's sequential events of fracture, refracture, and death were directly observed. As a result, the predicted risk inherently represents the likelihood of experiencing a fracture among those who are at risk for the remainder of their specific lifespan. In a study of hip fracture prediction among old women (average age 83) of Chinese background, the Garvan model performed better than FRAX and Qfracture [<xref rid="bib30" ref-type="bibr">29</xref>]. In the Geelong Osteoporosis Study [<xref rid="bib28" ref-type="bibr">27</xref>], the Garvan model underestimated fracture risk by around 25% in women and 19% in men, whereas FRAX underestimated it by 55% in women and 66% in men. In contrast, in the New Zealand cohort, the Garvan model predicted nearly 100% of fracture cases but overestimated hip fracture risk by 50%, while FRAX underestimated fracture risk by 50% [<xref rid="bib29" ref-type="bibr">28</xref>]. However, the Garvan model's overestimation has no negative clinical impact since high-risk individuals would be recommended for treatment regardless. There is evidence suggesting that the Garvan model's predicted risk is consistent with the clinical decision-making [<xref rid="bib31" ref-type="bibr">30</xref>,<xref rid="bib32" ref-type="bibr">31</xref>].</p>
    <p id="p0185">At present, the management of osteoporosis is in a crisis of an ‘osteoporosis treatment gap’ characterized by low treatment uptake among those at high risk. Hip fracture is the most serious consequence of osteoporosis because patients suffering from the fracture are at increased risk of mortality. There are treatments that have been shown to reduce the risk of refractures and mortality [<xref rid="bib33" ref-type="bibr">32</xref>,<xref rid="bib34" ref-type="bibr">33</xref>]. However, few patients with hip fractures were on treatment. In 2001, 40% of hip fracture patients were on treatment, and this proportion decreased to only 21 in 2011 [<xref rid="bib5" ref-type="bibr">5</xref>]. Moreover, among those on treatment, adherence has been poor [<xref rid="bib35" ref-type="bibr">34</xref>]. There are many reasons for the treatment gap, including the problem of risk communication. According to a qualitative study, patients who believed that osteoporosis was a natural part of aging, that treatment was ineffective, and that fractures were not serious chose not to pursue or discontinue treatment [<xref rid="bib36" ref-type="bibr">[35]</xref>, <xref rid="bib37" ref-type="bibr">[36]</xref>, <xref rid="bib38" ref-type="bibr">[37]</xref>]. Moreover, patients were more likely to accept treatment if they were presented with the benefit of treatment in terms of absolute risk reduction rather than relative risk reduction [<xref rid="bib39" ref-type="bibr">38</xref>]. Taken together, the research evidence indicates the necessity for innovative approaches to risk communication in order to enhance the adoption and compliance with anti-osteoporosis treatment.</p>
    <p id="p0190">Currently, patients are presented with fracture probabilities over a specific time frame without any quantitative information about the consequences of a fracture. Additionally, there is no clear indication of the survival advantages of treatment. To address these issues, BONEcheck was developed. BONEcheck not only offers absolute fracture risk assessments but also frames the absolute risk reduction and the survival benefits of treatment. This information can be valuable for facilitating productive discussions between doctors and patients regarding risk, treatment, and benefits. The risk information and treatment benefits are shown in the human icon array rather than in numerical format [<xref rid="bib40" ref-type="bibr">39</xref>].</p>
    <p id="p0195">In addition to offering a predicted risk of fracture, BONEcheck capitalizes on recent research to provide information on the skeletal age [<xref rid="bib20" ref-type="bibr">19</xref>]. Skeletal age is a way to understand the risk of fracture and its consequence of premature mortality. An individual's risk of fracture may be higher if the individual's skeletal age is greater than their chronological age. In this context, if an individual is 60 years old but has a skeletal age of 65, it implies that the individual's fracture risk matches that of a 65-year-old person with a 'healthy' risk profile or at least ones that can be modified. Previous studies suggested that conveying risk using biological age indicators, such as heart age, vascular age, lung age, and skeletal age, could potentially have a favorable influence on patient behavior [<xref rid="bib41" ref-type="bibr">40</xref>]. Since most fractures occur outside the high-risk (osteoporosis) group [<xref rid="bib42" ref-type="bibr">41</xref>], risk communication using skeletal age ('older than I actually am') can help raise awareness of the mortality consequence of fracture in those groups.</p>
    <p id="p0200">In addition to risk communication (eg, risk probability and skeletal age), BONEcheck also presents data on the estimated duration it would take for individuals who are currently not classified as having osteoporosis to develop the condition. This information can be especially useful for facilitating discussions between doctors and patients regarding the appropriate timeframe for repeating BMD measurements.</p>
    <p id="p0205">BONEcheck is the first tool that incorporates the polygenic risk score (PRS) to predict fracture risk. Several PRSes have been formulated [<xref rid="bib43" ref-type="bibr">[42]</xref>, <xref rid="bib44" ref-type="bibr">[43]</xref>, <xref rid="bib45" ref-type="bibr">[44]</xref>] based on the identification of genetic variants linked to BMD or fracture, in addition to our own [<xref rid="bib18" ref-type="bibr">17</xref>]. These PRSes utilize different genetic variants, but each has been validated as an independent predictor of fracture risk beyond clinical risk factors. Our PRS, which was created from 33 genetic variants associated with BMD, can replace family history as a fracture risk factor. Assessing the likelihood of fracture, or any disease risk, should be personalized because no "average individual" exists in the population, and each person is unique. An individual's distinctiveness can be characterized in terms of clinical risk factors, as well as PRS.</p>
    <p id="p0210">Nevertheless, a number of potential weaknesses should be acknowledged. The algorithms used to create BONEcheck were derived from data obtained from Caucasian populations which may have a higher fracture risk compared to Asian populations. Thus, the extrapolation of risk from BONEcheck to non-Caucasian requires certain adjustments. Comorbidity or concomitant diseases (<xref rid="tbl4" ref-type="table">Table 4</xref>) are largely based on self-report, and misclassification is a potential issue. Furthermore, there is a lack of evidence from randomized controlled trials indicating that intervening in individuals at high risk of fracture results in a decrease in fracture risk. Despite this, the output provided by BONEcheck can be beneficial for promoting discussions between doctors and patients regarding the prevention of osteoporotic fractures.<table-wrap position="float" id="tbl4"><label>Table 4</label><caption><p>Brief definition of comorbidity included in BONEcheck.</p></caption><alt-text id="alttext0040">Table 4</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Comorbidity</th><th>Definition</th></tr></thead><tbody><tr><td align="left">Cardiovascular disease</td><td align="left">Diseases of the heart and blood vessels.</td></tr><tr><td align="left">Neuromuscular disease</td><td align="left">Encompasses a range of conditions affecting the nerves and muscles.</td></tr><tr><td align="left">Chronic pulmonary disease</td><td align="left">Includes chronic conditions that affect the lungs and airways, such as chronic obstructive pulmonary disease (COPD) and asthma.</td></tr><tr><td align="left">Congestive heart failure</td><td align="left">Refers to a chronic condition where the heart is unable to pump blood efficiently.</td></tr><tr><td align="left">Rheumatologic disease</td><td align="left">Encompasses various conditions that affect the joints, muscles, and connective tissues, such as rheumatoid arthritis or systemic lupus erythematosus.</td></tr><tr><td align="left">Dementia</td><td align="left">Refers to a decline in cognitive abilities, memory loss, and other symptoms that significantly impact daily functioning.</td></tr><tr><td align="left">Mild liver disease</td><td align="left">Generally refers to mild liver dysfunction or liver abnormalities that do not severely impact liver function.</td></tr><tr><td align="left">Diabetes with chronic complications</td><td align="left">Includes diabetes cases where there are long-term complications resulting from the condition, such as kidney disease, nerve damage, or eye complications.</td></tr><tr><td align="left">Hemiplegia or paraplegia</td><td align="left">Hemiplegia refers to paralysis of one side of the body, while paraplegia refers to paralysis of the lower body.</td></tr><tr><td align="left">Renal disease</td><td align="left">Refers to diseases or conditions affecting the kidneys.</td></tr><tr><td align="left">Any malignancy including leukemia and lymphoma</td><td align="left">Encompasses all types of cancer, including leukemia and lymphoma.</td></tr><tr><td align="left">Moderate or severe liver disease</td><td align="left">Refers to liver dysfunction or abnormalities that significantly impact liver function.</td></tr><tr><td align="left">Metastatic solid tumor</td><td align="left">Refers to cancerous tumors that have spread to other parts of the body from the primary site.</td></tr><tr><td align="left">AIDS/HIV</td><td align="left">Refers to the human immunodeficiency virus (HIV) infection and the resulting acquired immunodeficiency syndrome (AIDS).</td></tr></tbody></table></table-wrap></p>
  </sec>
  <sec id="sec5">
    <label>5</label>
    <title>Conclusions</title>
    <p id="p0215">In conclusion, we have developed and implemented a digital tool called 'BONEcheck' for fracture risk assessment which is now available free worldwide. The tool can help facilitate doctor-patient discussion about fracture risk, clinical consequences, and treatment benefits so that an informed decision can be reached.</p>
  </sec>
  <sec id="sec6">
    <title>CRediT author statement</title>
    <p id="p0220"><bold>Dinh Tan Nguyen</bold>: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review &amp; editing.</p>
    <p id="p0225"><bold>Thao P. Ho-Le</bold>: Conceptualization, Methodology, Software, Supervision, Validation.</p>
    <p id="p0230"><bold>Liem Pham</bold>: Funding acquisition, Project administration, Resources, Software, Visualization.</p>
    <p id="p0235"><bold>Vinh P. Ho-Van</bold>: Data curation, Software.</p>
    <p id="p0240"><bold>Tien Dat Hoang</bold>: Data curation, Software.</p>
    <p id="p0245"><bold>Thach S. Tran</bold>: Formal analysis, Investigation, Methodology, Supervision, Validation, Writing – review &amp; editing.</p>
    <p id="p0250"><bold>Steve Frost</bold>: Conceptualization, Data curation, Investigation, Project administration.</p>
    <p id="p0255"><bold>Tuan V. Nguyen</bold>: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review &amp; editing.</p>
  </sec>
  <sec id="sec7">
    <title>Availability</title>
    <p id="p0260">BONEcheck is now accessible to users through multiple platforms. Users can access it directly from our website or download the app from the Apple Store or Google Play. Please click on the links below to start utilizing the BONEcheck tool:</p>
    <p id="p0265">Website: <ext-link ext-link-type="uri" xlink:href="https://bonecheck.org" id="intref0015">https://bonecheck.org</ext-link>.</p>
    <p id="p0270">Apple Store: <ext-link ext-link-type="uri" xlink:href="https://apps.apple.com/app/bonecheck/id6447424513" id="intref0020">https://apps.apple.com/app/bonecheck/id6447424513</ext-link>.</p>
    <p id="p0275">Google Play: <ext-link ext-link-type="uri" xlink:href="https://play.google.com/store/apps/details?id=org.saigonmec.bonecheck" id="intref0025">https://play.google.com/store/apps/details?id=org.saigonmec.bonecheck</ext-link>.</p>
    <p id="p0280">Auto access: <ext-link ext-link-type="uri" xlink:href="https://onelink.to/8cjb7m" id="intref0030">https://onelink.to/8cjb7m</ext-link>.</p>
    <p id="p0285">QR code:<inline-graphic xlink:href="fx1.gif"><alt-text id="alttext0025a">Image 1</alt-text></inline-graphic></p>
  </sec>
  <sec sec-type="COI-statement">
    <title>Conflicts of interest</title>
    <p id="p0290">Thach Tran, Thao Ho-Le, Dinh Nguyen, Vinh Ho-Van, Tien Hoang and Steve Frost have no competing interests to declare. Dinh Nguyen is supported by a grant from the <funding-source id="gs1">Medical Research Future Fund</funding-source> (grant number APP1176600). Tuan Van Nguyen has received grants from Australian <funding-source id="gs10"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source> and <funding-source id="gs11"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source> Competitive Grant Program; fees for lectures from <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source>, Bridge Health Care (VN), DKSH Pharma, <funding-source id="gs13">MSD</funding-source> and <funding-source id="gs14">VT</funding-source> Health Care (VN); and support from <funding-source id="gs15"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source> for attending the annual meeting of APCO and from <funding-source id="gs16">VT</funding-source> Health Care (VN) for attending the Vietnam Osteoporosis Society Annual Scientific Meeting. Dr. Nguyen is also Chair of the Research Committee for the Australian and New Zealand Bone and Mineral Society, a Senior Advisor for the Vietnam Osteoporosis Society, and an Executive Member of the Asia Pacific Consortium on Osteoporosis.</p>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <label>1</label>
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Sozen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ozisik</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Basaran</surname>
            <given-names>N.C.</given-names>
          </name>
        </person-group>
        <article-title>An overview and management of osteoporosis</article-title>
        <source>Eur J Rheumatol</source>
        <volume>4</volume>
        <issue>1</issue>
        <year>2017</year>
        <fpage>46</fpage>
        <lpage>56</lpage>
        <pub-id pub-id-type="pmid">28293453</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <label>2</label>
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Collaborators</surname>
            <given-names>G.B.D.F.</given-names>
          </name>
        </person-group>
        <article-title>Global, regional, and national burden of bone fractures in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019</article-title>
        <source>Lancet Healthy Longev</source>
        <volume>2</volume>
        <issue>9</issue>
        <year>2021</year>
        <fpage>e580</fpage>
        <lpage>e592</lpage>
        <pub-id pub-id-type="pmid">34723233</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <label>3</label>
      <element-citation publication-type="journal" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Bliuc</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Risk of subsequent fracture after low-trauma fracture in men and women</article-title>
        <source>JAMA</source>
        <volume>297</volume>
        <year>2007</year>
        <fpage>387</fpage>
        <lpage>394</lpage>
        <pub-id pub-id-type="pmid">17244835</pub-id>
      </element-citation>
    </ref>
    <ref id="bib4">
      <label>4</label>
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Bliuc</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Milch</surname>
            <given-names>V.E.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
        </person-group>
        <article-title>Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women</article-title>
        <source>JAMA</source>
        <volume>301</volume>
        <year>2009</year>
        <fpage>513</fpage>
        <lpage>521</lpage>
        <pub-id pub-id-type="pmid">19190316</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <label>5</label>
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Miller</surname>
            <given-names>P.D.</given-names>
          </name>
        </person-group>
        <article-title>Underdiagnosis and undertreatment of osteoporosis: the battle to be won</article-title>
        <source>J Clin Endocrinol Metab</source>
        <volume>101</volume>
        <year>2016</year>
        <fpage>852</fpage>
        <lpage>859</lpage>
        <pub-id pub-id-type="pmid">26909798</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <label>6</label>
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Frost</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Development of a nomogram for individualizing hip fracture risk in men and women</article-title>
        <source>Osteoporos Int</source>
        <volume>18</volume>
        <year>2007</year>
        <fpage>1109</fpage>
        <lpage>1117</lpage>
        <pub-id pub-id-type="pmid">17370100</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <label>7</label>
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Kanis</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Johnell</surname>
            <given-names>O.</given-names>
          </name>
          <name>
            <surname>Oden</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Johansson</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>McCloskey</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>FRAX and the assessment of fracture probability in men and women from the UK</article-title>
        <source>Osteoporos Int</source>
        <volume>19</volume>
        <year>2008</year>
        <fpage>385</fpage>
        <lpage>397</lpage>
        <pub-id pub-id-type="pmid">18292978</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <label>8</label>
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Trevena</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Zikmund-Fisher</surname>
            <given-names>B.J.</given-names>
          </name>
          <name>
            <surname>Edwards</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Gaissmaier</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Galesic</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>P.K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Presenting quantitative information about decision outcomes: a risk communication primer for patient decision aid developers</article-title>
        <source>BMC Med Inf Decis Making</source>
        <volume>13</volume>
        <issue>Suppl 2</issue>
        <year>2013</year>
        <fpage>S7</fpage>
      </element-citation>
    </ref>
    <ref id="bib9">
      <label>9</label>
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Gigerenzer</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Gaissmaier</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Kurz-Milcke</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Schwartz</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Woloshin</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>Helping doctors and patients make sense of health statistics</article-title>
        <source>Psychol Sci Publ Interest</source>
        <volume>8</volume>
        <year>2007</year>
        <fpage>53</fpage>
        <lpage>96</lpage>
      </element-citation>
    </ref>
    <ref id="bib10">
      <label>10</label>
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Frost</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Development of a nomogram for individualizing hip fracture risk in men and women</article-title>
        <source>Osteoporos Int</source>
        <volume>18</volume>
        <year>2007</year>
        <fpage>1109</fpage>
        <lpage>1117</lpage>
        <pub-id pub-id-type="pmid">17370100</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <label>11</label>
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Bliuc</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Pham</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Frost</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Epidemiological transition to mortality and refracture following an initial fracture</article-title>
        <source>eLife</source>
        <volume>10</volume>
        <year>2021</year>
      </element-citation>
    </ref>
    <ref id="bib12">
      <label>12</label>
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Tran</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Bliuc</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Abrahamsen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hansen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Vestergaard</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Skeletal Age’ for mapping the impact of fracture on mortality</article-title>
        <source>eLife</source>
        <volume>12</volume>
        <year>2023</year>
        <object-id pub-id-type="publisher-id">e83888</object-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <label>13</label>
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Frost</surname>
            <given-names>S.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>N.D.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Timing of repeat BMD measurements: development of an absolute risk-based prognostic model</article-title>
        <source>J Bone Miner Res</source>
        <volume>24</volume>
        <year>2009</year>
        <fpage>1800</fpage>
        <lpage>1807</lpage>
        <pub-id pub-id-type="pmid">19419321</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <label>14</label>
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Hillier</surname>
            <given-names>T.A.</given-names>
          </name>
        </person-group>
        <article-title>Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women</article-title>
        <source>Arch Intern Med</source>
        <volume>167</volume>
        <year>2007</year>
        <fpage>155</fpage>
        <pub-id pub-id-type="pmid">17242316</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <label>15</label>
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Charlson</surname>
            <given-names>M.E.</given-names>
          </name>
          <name>
            <surname>Pompei</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Ales</surname>
            <given-names>K.L.</given-names>
          </name>
          <name>
            <surname>MacKenzie</surname>
            <given-names>C.R.</given-names>
          </name>
        </person-group>
        <article-title>A new method of classifying prognostic comorbidity in longitudinal studies: development and validation</article-title>
        <source>J Chron Dis</source>
        <volume>40</volume>
        <year>1987</year>
        <fpage>373</fpage>
        <lpage>383</lpage>
        <pub-id pub-id-type="pmid">3558716</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <label>16</label>
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Styrkarsdottir</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Halldorsson</surname>
            <given-names>B.V.</given-names>
          </name>
          <name>
            <surname>Gretarsdottir</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gudbjartsson</surname>
            <given-names>D.F.</given-names>
          </name>
          <name>
            <surname>Walters</surname>
            <given-names>G.B.</given-names>
          </name>
          <name>
            <surname>Ingvarsson</surname>
            <given-names>T.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Multiple genetic loci for bone mineral density and fractures</article-title>
        <source>N Engl J Med</source>
        <volume>358</volume>
        <year>2008</year>
        <fpage>2355</fpage>
        <lpage>2365</lpage>
        <pub-id pub-id-type="pmid">18445777</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <label>17</label>
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>H.T.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Prediction of bone mineral density and fragility fracture by genetic profiling</article-title>
        <source>J Bone Miner Res</source>
        <volume>32</volume>
        <year>2017</year>
        <fpage>285</fpage>
        <lpage>293</lpage>
        <pub-id pub-id-type="pmid">27649491</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <label>18</label>
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Pham</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>H.T.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Prediction of changes in bone mineral density in the elderly: contribution of "osteogenomic profile"</article-title>
        <source>Arch Osteoporosis</source>
        <volume>13</volume>
        <year>2018</year>
        <fpage>68</fpage>
      </element-citation>
    </ref>
    <ref id="bib20">
      <label>19</label>
      <element-citation publication-type="journal" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Tran</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Bliuc</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Abrahamsen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Hansen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Vestergaard</surname>
            <given-names>P.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>‘Skeletal Age’ for mapping the impact of fracture on mortality</article-title>
        <source>eLife</source>
        <volume>12</volume>
        <year>2023</year>
        <object-id pub-id-type="publisher-id">e83888</object-id>
      </element-citation>
    </ref>
    <ref id="bib21">
      <label>20</label>
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Andersen</surname>
            <given-names>P.K.</given-names>
          </name>
        </person-group>
        <article-title>Life years lost among patients with a given disease</article-title>
        <source>Stat Med</source>
        <volume>36</volume>
        <year>2017</year>
        <fpage>3573</fpage>
        <lpage>3582</lpage>
        <pub-id pub-id-type="pmid">28585255</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <label>21</label>
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
        </person-group>
        <article-title>Femoral neck bone loss predicts fracture risk independent of baseline BMD</article-title>
        <source>J Bone Miner Res</source>
        <volume>20</volume>
        <year>2005</year>
        <fpage>1195</fpage>
        <lpage>1201</lpage>
        <pub-id pub-id-type="pmid">15940372</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <label>22</label>
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Ensrud</surname>
            <given-names>K.E.</given-names>
          </name>
          <name>
            <surname>Palermo</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Black</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Cauley</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jergas</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Orwoll</surname>
            <given-names>E.S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hip and calcaneal bone loss increase with advancing age: longitudinal results from the study of osteoporotic fractures</article-title>
        <source>J Bone Miner Res</source>
        <volume>10</volume>
        <year>1995</year>
        <fpage>1778</fpage>
        <lpage>1787</lpage>
        <pub-id pub-id-type="pmid">8592956</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <label>23</label>
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Cummings</surname>
            <given-names>S.R.</given-names>
          </name>
          <name>
            <surname>San Martin</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>McClung</surname>
            <given-names>M.R.</given-names>
          </name>
          <name>
            <surname>Siris</surname>
            <given-names>E.S.</given-names>
          </name>
          <name>
            <surname>Eastell</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Reid</surname>
            <given-names>I.R.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Denosumab for prevention of fractures in postmenopausal women with osteoporosis</article-title>
        <source>N Engl J Med</source>
        <volume>361</volume>
        <year>2009</year>
        <fpage>756</fpage>
        <lpage>765</lpage>
        <pub-id pub-id-type="pmid">19671655</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <label>24</label>
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Khosla</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>N.C.</given-names>
          </name>
          <name>
            <surname>Elderkin</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Kiel</surname>
            <given-names>D.P.</given-names>
          </name>
        </person-group>
        <article-title>Osteoporosis in the USA: prevention and unmet needs</article-title>
        <source>Lancet Diabetes Endocrinol</source>
        <volume>11</volume>
        <year>2023</year>
        <fpage>19</fpage>
        <lpage>20</lpage>
        <pub-id pub-id-type="pmid">36395774</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <label>25</label>
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Hippisley-Cox</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Coupland</surname>
            <given-names>C.</given-names>
          </name>
        </person-group>
        <article-title>Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study</article-title>
        <source>BMJ</source>
        <volume>344</volume>
        <year>2012</year>
        <fpage>e3427</fpage>
        <pub-id pub-id-type="pmid">22619194</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <label>26</label>
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Individualized fracture risk assessment: state-of-the-art and room for improvement</article-title>
        <source>Osteoporos Sarcopenia</source>
        <volume>4</volume>
        <year>2018</year>
        <fpage>2</fpage>
        <lpage>10</lpage>
        <pub-id pub-id-type="pmid">30775534</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <label>27</label>
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Holloway-Kew</surname>
            <given-names>K.L.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Betson</surname>
            <given-names>A.G.</given-names>
          </name>
          <name>
            <surname>Anderson</surname>
            <given-names>K.B.</given-names>
          </name>
          <name>
            <surname>Hans</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Hyde</surname>
            <given-names>N.K.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>How well do the FRAX (Australia) and Garvan calculators predict incident fractures? Data from the Geelong Osteoporosis Study</article-title>
        <source>Osteoporos Int</source>
        <volume>30</volume>
        <year>2019</year>
        <fpage>2129</fpage>
        <lpage>2139</lpage>
        <pub-id pub-id-type="pmid">31317250</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <label>28</label>
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Bolland</surname>
            <given-names>M.J.</given-names>
          </name>
          <name>
            <surname>Siu</surname>
            <given-names>A.T.</given-names>
          </name>
          <name>
            <surname>Mason</surname>
            <given-names>B.H.</given-names>
          </name>
          <name>
            <surname>Horne</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Ames</surname>
            <given-names>R.W.</given-names>
          </name>
          <name>
            <surname>Grey</surname>
            <given-names>A.B.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Evaluation of the FRAX and Garvan fracture risk calculators in older women</article-title>
        <source>J Bone Miner Res</source>
        <volume>26</volume>
        <year>2011</year>
        <fpage>420</fpage>
        <lpage>427</lpage>
        <pub-id pub-id-type="pmid">20721930</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <label>29</label>
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Lam</surname>
            <given-names>M.T.</given-names>
          </name>
          <name>
            <surname>Sing</surname>
            <given-names>C.W.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>G.H.Y.</given-names>
          </name>
          <name>
            <surname>Kung</surname>
            <given-names>A.W.C.</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>K.C.B.</given-names>
          </name>
          <name>
            <surname>Cheung</surname>
            <given-names>C.L.</given-names>
          </name>
        </person-group>
        <article-title>Development and validation of a risk score to predict the first hip fracture in the oldest old: a Retrospective Cohort Study</article-title>
        <source>J Gerontol A Biol Sci Med Sci</source>
        <volume>75</volume>
        <year>2020</year>
        <fpage>980</fpage>
        <lpage>986</lpage>
        <pub-id pub-id-type="pmid">31353417</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <label>30</label>
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Inderjeeth</surname>
            <given-names>C.A.</given-names>
          </name>
          <name>
            <surname>Raymond</surname>
            <given-names>W.D.</given-names>
          </name>
        </person-group>
        <article-title>Case finding with GARVAN fracture risk calculator in primary prevention of fragility fractures in older people</article-title>
        <source>Arch Gerontol Geriatr</source>
        <volume>86</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">103940</object-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <label>31</label>
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Stuckey</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Magraith</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Opie</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>K.</given-names>
          </name>
        </person-group>
        <article-title>Fracture risk prediction and the decision to treat low bone density</article-title>
        <source>Aust J Gen Pract</source>
        <volume>50</volume>
        <year>2021</year>
        <fpage>165</fpage>
        <lpage>170</lpage>
        <pub-id pub-id-type="pmid">33634286</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <label>32</label>
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Lyles</surname>
            <given-names>K.W.</given-names>
          </name>
          <name>
            <surname>Colon-Emeric</surname>
            <given-names>C.S.</given-names>
          </name>
          <name>
            <surname>Magaziner</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Adachi</surname>
            <given-names>J.D.</given-names>
          </name>
          <name>
            <surname>Pieper</surname>
            <given-names>C.F.</given-names>
          </name>
          <name>
            <surname>Mautalen</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Zoledronic acid and clinical fractures and mortality after hip fracture</article-title>
        <source>N Engl J Med</source>
        <volume>357</volume>
        <year>2007</year>
        <fpage>1799</fpage>
        <lpage>1809</lpage>
        <pub-id pub-id-type="pmid">17878149</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <label>33</label>
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Reid</surname>
            <given-names>I.R.</given-names>
          </name>
          <name>
            <surname>Horne</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Mihov</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Stewart</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Garratt</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Bastin</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women</article-title>
        <source>J Bone Miner Res</source>
        <volume>35</volume>
        <year>2020</year>
        <fpage>20</fpage>
        <lpage>27</lpage>
        <pub-id pub-id-type="pmid">31603996</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <label>34</label>
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Fatoye</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Gebrye</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Yeowell</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review</article-title>
        <source>BMJ Open</source>
        <volume>9</volume>
        <year>2019</year>
        <object-id pub-id-type="publisher-id">e027049</object-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <label>35</label>
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Salter</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Brainard</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>McDaid</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Loke</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>Challenges and opportunities: what can we learn from patients living with chronic musculoskeletal conditions, health professionals and carers about the concept of health literacy using qualitative methods of inquiry?</article-title>
        <source>PLoS One</source>
        <volume>9</volume>
        <year>2014</year>
        <object-id pub-id-type="publisher-id">e112041</object-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <label>36</label>
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>Hawarden</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Jinks</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Mahmood</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Bullock</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Blackburn</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Gwilym</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Public priorities for osteoporosis and fracture research: results from a focus group study</article-title>
        <source>Arch Osteoporosis</source>
        <volume>15</volume>
        <year>2020</year>
        <fpage>89</fpage>
      </element-citation>
    </ref>
    <ref id="bib38">
      <label>37</label>
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Paskins</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Crawford-Manning</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Cottrell</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Corp</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Jinks</surname>
            <given-names>C.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Acceptability of bisphosphonates among patients, clinicians and managers: a systematic review and framework synthesis</article-title>
        <source>BMJ Open</source>
        <volume>10</volume>
        <year>2020</year>
        <object-id pub-id-type="publisher-id">e040634</object-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <label>38</label>
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Ralston</surname>
            <given-names>K.A.P.</given-names>
          </name>
          <name>
            <surname>Phillips</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Krause</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Hauser</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Ralston</surname>
            <given-names>S.H.</given-names>
          </name>
        </person-group>
        <article-title>Communicating absolute fracture risk reduction and the acceptance of treatment for osteoporosis</article-title>
        <source>Calcif Tissue Int</source>
        <volume>110</volume>
        <year>2022</year>
        <fpage>698</fpage>
        <lpage>702</lpage>
        <pub-id pub-id-type="pmid">35152304</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <label>39</label>
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Elwyn</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Price</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Franco</surname>
            <given-names>J.V.A.</given-names>
          </name>
          <name>
            <surname>Gulbrandsen</surname>
            <given-names>P.</given-names>
          </name>
        </person-group>
        <article-title>The limits of shared decision making</article-title>
        <source>BMJ Evid Based Med</source>
        <volume>28</volume>
        <year>2023</year>
        <fpage>218</fpage>
        <lpage>221</lpage>
      </element-citation>
    </ref>
    <ref id="bib41">
      <label>40</label>
      <element-citation publication-type="journal" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Kulendrarajah</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Grey</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nunan</surname>
            <given-names>D.</given-names>
          </name>
        </person-group>
        <article-title>How effective are 'age' tools at changing patient behaviour? A rapid review</article-title>
        <source>BMJ Evid Based Med</source>
        <volume>25</volume>
        <year>2020</year>
        <fpage>1</fpage>
        <lpage>2</lpage>
      </element-citation>
    </ref>
    <ref id="bib42">
      <label>41</label>
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Mai</surname>
            <given-names>H.T.</given-names>
          </name>
          <name>
            <surname>Tran</surname>
            <given-names>T.S.</given-names>
          </name>
          <name>
            <surname>Ho-Le</surname>
            <given-names>T.P.</given-names>
          </name>
          <name>
            <surname>Center</surname>
            <given-names>J.R.</given-names>
          </name>
          <name>
            <surname>Eisman</surname>
            <given-names>J.A.</given-names>
          </name>
          <name>
            <surname>Nguyen</surname>
            <given-names>T.V.</given-names>
          </name>
        </person-group>
        <article-title>Two-thirds of all fractures are not attributable to osteoporosis and advancing age: implication for fracture prevention</article-title>
        <source>J Clin Endocrinol Metab</source>
        <volume>104</volume>
        <year>2019</year>
        <fpage>3514</fpage>
        <lpage>3520</lpage>
        <pub-id pub-id-type="pmid">30951170</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <label>42</label>
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>E.H.</given-names>
          </name>
          <name>
            <surname>Ahn</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>K.H.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>B.J.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Prediction of future osteoporotic fracture occurrence by genetic profiling: a 6-year follow-up observational study</article-title>
        <source>J Clin Endocrinol Metab</source>
        <volume>101</volume>
        <year>2016</year>
        <fpage>1215</fpage>
        <lpage>1224</lpage>
        <pub-id pub-id-type="pmid">26756118</pub-id>
      </element-citation>
    </ref>
    <ref id="bib44">
      <label>43</label>
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Eriksson</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Evans</surname>
            <given-names>D.S.</given-names>
          </name>
          <name>
            <surname>Nielson</surname>
            <given-names>C.M.</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Srikanth</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Hochberg</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Limited clinical utility of a genetic risk score for the prediction of fracture risk in elderly subjects</article-title>
        <source>J Bone Miner Res</source>
        <volume>30</volume>
        <year>2015</year>
        <fpage>184</fpage>
        <lpage>194</lpage>
        <pub-id pub-id-type="pmid">25043339</pub-id>
      </element-citation>
    </ref>
    <ref id="bib45">
      <label>44</label>
      <element-citation publication-type="journal" id="sref45">
        <person-group person-group-type="author">
          <name>
            <surname>Lu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Forgetta</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Keller-Baruch</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Nethander</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bennett</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Forest</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Improved prediction of fracture risk leveraging a genome-wide polygenic risk score</article-title>
        <source>Genome Med</source>
        <volume>13</volume>
        <year>2021</year>
        <fpage>16</fpage>
        <pub-id pub-id-type="pmid">33536041</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0295">The development of BONEcheck is supported in part by a grant from the <funding-source id="gs17"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000925</institution-id><institution>National Health and Medical Research Council in Australia</institution></institution-wrap></funding-source> (APP1195305) and <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100002429</institution-id><institution>Amgen</institution></institution-wrap></funding-source> Competitive Grant Program (2019). Neither the funding sources nor the authors' institutions had any role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit this manuscript for publication. <bold>ORCID</bold> Dinh Tan Nguyen: 0000-0002-9749-6924. Thao P. Ho-Le: 0000-0002-8387-1893. Liem Pham: 0009-0004-7612-842X. Vinh P. Ho-Van: 0009-0007-3965-9514. Tien Dat Hoang: 0009-0000-8839-2499. Thach S. Tran: 0000-0002-6454-124X. Steve Frost: 0000-0002-8879-0486. Tuan V. Nguyen: 000-0002-3246-6281.</p>
  </ack>
  <fn-group>
    <fn id="d35e853">
      <p id="ntpara0010">Peer review under responsibility of The Korean Society of Osteoporosis.</p>
    </fn>
  </fn-group>
</back>
